Literature DB >> 1119389

Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate.

B Befeler, A Castellanos, D E Wells, M C Vagueiro, B K Yeh.   

Abstract

The electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate given intravenously were studied in 10 patients with cardiac disease. Studies included determinations of sinus recovery time and refractoriness of the atria, the atrioventricular (A-V) node and the His-Purkinje system. Measurements were performed at rest and 15 and 30 minutes after administration of disopyramide. Serum drug levels were measured at these times. Sinus recovery time was shortened at both 15 and 30 minutes, with an average decrease of 39.5 and 146.2 msec, respectively (P less than 0.01). Atrial refractoriness was not altered significantly, but tended to be reduced; the mean effective refractory period was 289.5 msec before administration of disopyramide and 259 and 270 msec 15 and 30 minutes, respectively, after administration. The functional refractory period of the atrioventricular (A-V) node was definitely prolonged in seven patients 15 minutes after administration of disopyramide. The relative refractory period of the His-Purkinje System was not altered. Although this study does not elucidate the mechanism by which disopyramide acheives its antiarrhythmic effects, animal work has shown that it is similar to that of quinidine. In the doses used the drug does not seem to cause first, second or third degree A-V block or fascicular or bundle branch block; it did not increase the severity of first degree A-V block in the three patients with this disturbance. The drug may be particularly useful when arrhythmias are associated with slow sinus rates.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1119389     DOI: 10.1016/0002-9149(75)90014-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: correlation of the kinetics of the drug and its effects.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

3.  Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods.

Authors:  J S Birkhead; E M Vaughan Williams
Journal:  Br Heart J       Date:  1977-06

4.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

5.  Efficacy of intravenous disopyramide in acute cardiac arrhythmias.

Authors:  M De Backer; E Stoupel; R J Kahn
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

6.  [The effect of disopyramide of left ventricular function: an echocardiographic study of the extent and time course (author's transl)].

Authors:  C Angermann; G Autenrieth
Journal:  Klin Wochenschr       Date:  1981-07-15

Review 7.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

Review 8.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

9.  Selective blockade of retrograde fast pathway by intravenous disopyramide in paroxysmal supraventricular tachycardia mediated by dual atrioventricular nodal pathways.

Authors:  K K Sethi; S Jaishankar; M Khalilullah; M P Gupta
Journal:  Br Heart J       Date:  1983-06

10.  Extreme tachycardia complicating the use of disopyramide in atrial flutter.

Authors:  C E Robertson; H C Miller
Journal:  Br Heart J       Date:  1980-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.